Ajanta Pharma Limited
3,270.60
INR
+10.40
(+0.32%)
ISIN
INE031B01049
Return %
Stock
S&P 500
1Y
33.62
14.20
3Y
86.52
81.12
5Y
127.19
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Yogesh Mannalal Agrawal
- Full Time Employees
- 13,206
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ajanta House Mumbai MA India 400 093
- IPO Date
- Jun 5, 2000
- Website
- ajantapharma.com
- Similar Companies
- Business
- Ajanta Pharma Limited (AJANTPHARM.NS) is an Indian multinational specialty pharmaceutical company that develops, manufactures and markets branded generic medicines and US generics across chronic and acute therapies; offers products in ophthalmology (glaucoma, dry eye, conjunctivitis treatments), cardiology (antihypertensives, heart failure, cholesterol control), dermatology (acne, psoriasis, fungal infections, allergies), pain management (analgesics, anti-inflammatories), anti-malarials, antidiabetics, anti-allergics, antibiotics, respiratory, gastroenterology, gynecology, nephrology and central nervous system segments; and provides dosage forms including tablets, capsules, injectables, inhalers, ointments and sterile eye drops. The company operates in 30+ countries including India, Southeast Asia, Middle East, Central Asia, Africa (20 countries) and the United States, with 74% of revenue from branded generics in India (32%), Asia (26%) and Africa (16%), 23% from US generics and 3% from Africa institutional anti-malarials. Founded in 1973 and headquartered in Mumbai, India, Ajanta Pharma employs over 11,000 people across seven state-of-the-art manufacturing facilities in India (six for finished formulations including Paithan, Guwahati, Pithampur and Dahej; one for APIs primarily for captive use), with approvals from US FDA and WHO. Ajanta Pharma maintains leadership in multiple molecules and sub-therapeutic segments through first-to-market products (50% of portfolio), covering 2.5+ lakh doctors in India with 5,400+ medical representatives globally and focusing on chronic therapies that contribute 65% of India sales. The company invests 5% of revenue in R&D with 850+ scientists developing complex formulations, supported by 52 active ANDAs (47 products on shelf) and 22 under approval for US generics. In emerging markets, it holds top-5 positions in key countries with 500+ brands, while its robust supply chain ensures 99.9% fill rates in the US. In recent developments, Ajanta Pharma acquired three pain management brands from Aksigen (annual revenue Rs. 15-17 crore) in FY2025 to strengthen its India portfolio, entered nephrology and gynecology therapies with over 200 medical representatives, expanded field force by 250 in existing therapies, launched 32 new products in India (8 first-to-market, including 6 in Q4 FY2025) contributing to 11% growth outperforming IPM's 8%, introduced 38 new products in Asia/Africa (25 in Asia chronic therapies, 13 in Africa), and launched 5 US generics in H2 FY2025 (e.g., Fluvoxamine ER, Oxcarbazepine/Oxtellar XR). The company added capacity at its Pithampur liquid formulation facility to 12 million bottles per annum (from 6 million, investment Rs. 92 crore, expected Q1 FY2026) for emerging markets demand, invested Rs. 318 crore in capex including new liquid plant and office, and grew consolidated revenue 10% to Rs. 4,588 crore with PAT up 13% to Rs. 920 crore in FY2025.